BR112019023336A2 - Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação - Google Patents

Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação Download PDF

Info

Publication number
BR112019023336A2
BR112019023336A2 BR112019023336-9A BR112019023336A BR112019023336A2 BR 112019023336 A2 BR112019023336 A2 BR 112019023336A2 BR 112019023336 A BR112019023336 A BR 112019023336A BR 112019023336 A2 BR112019023336 A2 BR 112019023336A2
Authority
BR
Brazil
Prior art keywords
therapy
useful
preparation
conjugates
peptidic
Prior art date
Application number
BR112019023336-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Bouchard Hervé
Brun Marie-Priscille
Hubert Philippe
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of BR112019023336A2 publication Critical patent/BR112019023336A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112019023336-9A 2017-05-10 2018-05-09 Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação BR112019023336A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305531.0 2017-05-10
EP17305531 2017-05-10
PCT/EP2018/061989 WO2018206635A1 (en) 2017-05-10 2018-05-09 Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation

Publications (1)

Publication Number Publication Date
BR112019023336A2 true BR112019023336A2 (pt) 2020-06-16

Family

ID=58873750

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019023336-9A BR112019023336A2 (pt) 2017-05-10 2018-05-09 Ligantes peptídicos e conjugados de criptoficina, úteis em terapia, e sua preparação

Country Status (21)

Country Link
US (5) US20180369401A1 (cg-RX-API-DMAC7.html)
EP (1) EP3621658A1 (cg-RX-API-DMAC7.html)
JP (2) JP2020519610A (cg-RX-API-DMAC7.html)
KR (1) KR102722886B1 (cg-RX-API-DMAC7.html)
CN (1) CN110831633A (cg-RX-API-DMAC7.html)
AR (1) AR111781A1 (cg-RX-API-DMAC7.html)
AU (2) AU2018265333C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019023336A2 (cg-RX-API-DMAC7.html)
CA (1) CA3062977A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019012108A2 (cg-RX-API-DMAC7.html)
EA (1) EA201992667A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19078277A (cg-RX-API-DMAC7.html)
IL (1) IL270507B2 (cg-RX-API-DMAC7.html)
MA (1) MA50764A (cg-RX-API-DMAC7.html)
MX (1) MX2019013421A (cg-RX-API-DMAC7.html)
MY (1) MY204075A (cg-RX-API-DMAC7.html)
PH (1) PH12019550230A1 (cg-RX-API-DMAC7.html)
TN (1) TN2019000303A1 (cg-RX-API-DMAC7.html)
TW (1) TWI778059B (cg-RX-API-DMAC7.html)
UY (1) UY37728A (cg-RX-API-DMAC7.html)
WO (1) WO2018206635A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
IL267709B2 (en) 2016-12-30 2025-04-01 Vaxcyte Inc Polypeptide-antigen conjugates with unnatural amino acids
WO2018206635A1 (en) 2017-05-10 2018-11-15 Sanofi Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
CN111154133B (zh) * 2020-01-03 2022-07-12 万华化学集团股份有限公司 一种环氧树脂发泡剂,环氧树脂组合物及环氧发泡材料的制备方法和用途
CN114053426B (zh) * 2020-07-30 2024-06-18 成都科岭源医药技术有限公司 一种双药链接组装单元及双药靶向接头-药物偶联物
CN115105607B (zh) * 2021-03-22 2024-12-20 成都科岭源医药技术有限公司 一种用于adc的双药-接头的制备方法及其用途
KR20240016287A (ko) * 2021-06-01 2024-02-06 아지노모토 가부시키가이샤 항체 및 기능성 물질의 콘쥬게이트 또는 이의 염, 및 이의 제조에 사용되는 화합물 또는 이의 염
KR20240150807A (ko) 2022-02-22 2024-10-16 아라리스 바이오테크 아게 2개 이상의 페이로드를 포함하는 펩티드 링커
CN115212315A (zh) * 2022-08-03 2022-10-21 联宁(苏州)生物制药有限公司 一种抗体偶联药物中间体及含有其的抗体偶联药物
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors
WO2026013234A1 (en) 2024-07-10 2026-01-15 Araris Biotech Ag Triple-payload antibody-drug conjugates (adcs)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4040907A (en) * 1974-06-20 1977-08-09 Syva Company Iodothyronine enzyme conjugates
ATE203016T1 (de) 1993-12-21 2001-07-15 Univ Hawaii Cryptophycine
WO1998008505A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Pharmaceutical compounds
US20020128185A1 (en) 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
BRPI0812970A2 (pt) * 2007-06-25 2019-09-24 Endocyte Inc conjugados contendo espaçadores hidrofílicos
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
US8953557B2 (en) 2009-06-30 2015-02-10 Alcatel Lucent Roaming method for a mobile terminal in WLAN, related access controller and access point device
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
AU2014337317A1 (en) * 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
PT3057585T (pt) 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
US10758636B2 (en) * 2013-11-12 2020-09-01 Centre For Probe Development And Commercialization Residualizing linkers and uses thereof
WO2016065142A2 (en) 2014-10-22 2016-04-28 The Johns Hopkins University New scaffolds and multifunctional intermediates for imaging psma and cancer therapy
EP3229844B1 (en) * 2014-12-09 2020-03-04 AbbVie Inc. Antibody drug conjugates with cell permeable bcl-xl inhibitors
CN107849146A (zh) * 2015-04-21 2018-03-27 艾伯维施特姆森特克斯有限责任公司 卡奇霉素构建体和使用方法
TWI714661B (zh) * 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
WO2018206635A1 (en) 2017-05-10 2018-11-15 Sanofi Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation

Also Published As

Publication number Publication date
KR102722886B1 (ko) 2024-10-29
CA3062977A1 (en) 2018-11-15
TN2019000303A1 (en) 2021-05-07
US11998611B2 (en) 2024-06-04
MA50764A (fr) 2020-03-18
KR20200005580A (ko) 2020-01-15
CN110831633A (zh) 2020-02-21
TWI778059B (zh) 2022-09-21
EA201992667A1 (ru) 2020-03-10
AU2022204711C1 (en) 2025-04-24
US20210228726A1 (en) 2021-07-29
MY204075A (en) 2024-08-06
IL270507B1 (en) 2023-04-01
PH12019550230A1 (en) 2020-07-06
AU2022204711B9 (en) 2025-01-23
JP2023085475A (ja) 2023-06-20
US20180369401A1 (en) 2018-12-27
JP2020519610A (ja) 2020-07-02
AU2022204711B2 (en) 2024-01-04
MX2019013421A (es) 2020-02-05
TW201907957A (zh) 2019-03-01
AU2022204711A1 (en) 2022-07-21
AU2018265333C1 (en) 2025-04-24
AU2018265333A1 (en) 2019-11-28
WO2018206635A1 (en) 2018-11-15
US11007275B2 (en) 2021-05-18
UY37728A (es) 2019-01-02
ECSP19078277A (es) 2019-11-30
IL270507A (cg-RX-API-DMAC7.html) 2019-12-31
US20200093934A1 (en) 2020-03-26
EP3621658A1 (en) 2020-03-18
AU2018265333B2 (en) 2022-07-21
CO2019012108A2 (es) 2020-02-28
US20250205348A1 (en) 2025-06-26
IL270507B2 (en) 2023-08-01
AR111781A1 (es) 2019-08-21
US20200054760A1 (en) 2020-02-20

Similar Documents

Publication Publication Date Title
CO2019012108A2 (es) Nuevos ligadores peptídicos y conjugados de criptoficina, su preparación y su uso terapéutico
PH12020551959A1 (en) Fxr (nr1h4) modulating compounds
MX385718B (es) Compuestos moduladores de fxr (nr1h4).
MX2017007981A (es) Compuestos que contienen hidroxi moduladores de fxr (nr1h4).
BR112014029706A8 (pt) Composto, composição farmacêutica, e, uso de um composto
MX2017007522A (es) Compuestos moduladores del receptor x farnesoide (frx) (receptor nr1h4) novedosos.
MX374535B (es) Compuestos de criptoficina novedosos y productos conjugados, su preparacion y su uso terapeutico.
BR112014010183B8 (pt) Composto, composição farmacêutica, produto, e, uso de um composto
CL2009001065A1 (es) Compuestos derivados de 4-pirimidinil-1,3-tiazol (o 1,3-oxazol) sulfonamidas sustituidas, inhibidores de quinasas raf; composicion farmaceutica; procedimiento de preparacion; y uso para tratar un neoplasma susceptible, seleccionado de adenocarcinoma de barret, carcinomas del tracto biliar y cancer de seno, entre otros.
MX2020012695A (es) Compuestos de benceno substituidos con arilo o heteroarilo.
BRPI1011043B8 (pt) fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, seus usos e seu processo de preparação, e composição farmacêutica
CL2014001880A1 (es) Composición farmacéutica de quitosana glicada viscoelástica; uso para tratar el cáncer; y uso para acondicionar un neoplasma para tratamiento fotofísico e inmunológico combinado.
BR112016027383A8 (pt) derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
BR112018013271A2 (pt) composições e métodos para detectar e tratar câncer de ovário
MX2014009244A (es) Una composicion y uso de la misma en el tratamiento de ragades anales.
BR112017012022A2 (pt) complexos macromoleculares de metais de transição para o tratamento do cancro e seu processo de preparação
BRPI0909142B8 (pt) composto cíclico e sal do mesmo, seu uso, seu processo de preparação, e composição farmacêutica
BR112016002724A8 (pt) composto, processo para a preparação de um composto, composição farmacêutica e uso de composto
BR112015005560A2 (pt) derivados de macrolídeos, sua preparação e seu uso terapêutico
BR112015024571A2 (pt) compostos de complexo de ferro(iii), medicamento, e, composição
PL418655A1 (pl) Kwas 3,7,11,15-tetrametylo-3-winyloheksadekanowy oraz sposób otrzymywania kwasu 3,7,11,15-tetrametylo-3-winyloheksadekanowego
BR112016002752A8 (pt) Anticorpo ou seus fragmentos funcionais que pode especificamente se ligar ao her2, polinucleotídeo isolado, combinação dos polinucleotídeos isolados, vetor de expressão, conjugado, conjugado com a fórmula geral ab-(l-u)n, composição farmacêutica e uso do anticorpo ou seus fragmentos funcionais
UA95390U (uk) Спосіб одержання комплексного нанометалоглобулінового препарату

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ARQUIVADO O PEDIDO DE PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 8A RETRIBUICAO ANUAL.PARA FINS DE RESTAURACAO CONFORME ARTIGO 87, DA LPI 9.279, E ARTIGO 15, DA PORTARIA 52/2023, O DEPOSITANTE DEVERA, NO PRAZO DE 3 (TRES) MESES, PROCEDER COM:- PAGAMENTO DA GRU SERVICO 208, REFERENTE A TAXA DE RESTAURACAO DO PEDIDO.- PAGAMENTO DE 1 (UMA) GRU, SERVICO 221, REFERENTE A ANUIDADE EM QUESTAO, NO VALOR EXTRAORDINARIO, CONFORME TABELA VIGENTE, SEGUNDO O ART. 84O 2O DA LEI NO 9.279/96. CASO NAO HAJA PAGAMENTO CONJUNTO, DENTRO DO PRAZO LEGAL, DAS RETRIBUICOES SUPRACITADAS, SERA MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, ATRAVES DO DE